<!DOCTYPE html>
<html lang="en-US"><head>
		<meta charset="UTF-8">
		<title>FR940127-1-00067</title>
	</head>
	<body>
		<main>
			<p><!-- PJG ITAG l=10 g=1 f=2 --> DATES: <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 -->  Comments by March 28, 1994. <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline --> <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG FTAG 4717 -->  <!-- PJG STAG 4717 -->  <!-- PJG ITAG l=01 g=1 f=1 --> Thursday <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=02 g=1 f=1 --> January 27, 1994 <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=09 g=1 f=1 -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=03 g=1 f=1 --> Part III <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=04 g=1 f=1 --> Department of Health and Human Services <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=09 g=1 f=1 -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=05 g=1 f=1 --> Food and Drug Administration <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=09 g=1 f=1 -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=05 g=1 f=1 --> 21 CFR Part 20 <!-- PJG 0012 frnewline --> Protecting Identities of Reporters of Adverse Events and Patients; Proposed Rule <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG /STAG -->  <!-- PJG /FTAG -->  <!-- PJG FTAG 4701 -->  <!-- PJG STAG 4701 -->  <!-- PJG ITAG l=90 g=1 f=1 -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=90 g=1 f=4 --> Federal Register <!-- PJG /ITAG -->  <!-- PJG ITAG l=90 g=1 f=1 --> &blank;/&blank;Vol. 59, No. 18&blank;/&blank; Thursday, January 27, 1994&blank;/&blank;Proposed Rules <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=52 g=1 f=1 -->  <USDEPT>DEPARTMENT OF HEALTH AND HUMAN SERVICES </USDEPT>  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=18 g=1 f=1 -->  <USBUREAU>Food And Drug Administration</USBUREAU> <!-- PJG /ITAG -->  <!-- PJG ITAG l=52 g=1 f=1 --> 21 CFR PART 20  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=41 g=1 f=1 -->  <RINDOCK>[Docket No. 93N&hyph;0334] </RINDOCK> <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG /STAG -->  <!-- PJG /FTAG -->  <!-- PJG STAG 4704 -->  <!-- PJG ITAG l=55 g=1 f=1 --> Protecting the Identities of Reporters of Adverse Events and  <!-- PJG 0012 frnewline --> Patients; Preemption of Disclosure Rules  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG /STAG -->  <!-- PJG STAG 4703 -->  <AGENCY> <!-- PJG ITAG l=10 g=1 f=2 --> AGENCY: <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 -->  Food and Drug Administration, HHS.  <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline --> </AGENCY> <ACTION> <!-- PJG ITAG l=10 g=1 f=2 --> ACTION: <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 -->  Proposed rule.  <!-- PJG /ITAG -->  <!-- PJG ITAG l=59 g=1 f=1 -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </ACTION> <SUMMARY> <!-- PJG ITAG l=10 g=1 f=2 --> SUMMARY: <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 -->  The Food and Drug Administration (FDA) is proposing to  <!-- PJG 0012 frnewline --> amend its public information regulations to help ensure that the  <!-- PJG 0012 frnewline --> identities of those who report adverse events associated with  <!-- PJG 0012 frnewline --> human drugs, biologics, and medical devices, and the identities  <!-- PJG 0012 frnewline --> of patients are held in confidence and not disclosed by FDA, as  <!-- PJG 0012 frnewline --> provided in current agency rules, or by manufacturers that  <!-- PJG 0012 frnewline --> possess these reports. The proposed rule is intended to preempt  <!-- PJG 0012 frnewline --> the establishment or continuation in effect of any State or local  <!-- PJG 0012 frnewline --> law, rule, regulation, or other requirement that requires or  <!-- PJG 0012 frnewline --> permits disclosure of such identities. This action is being  <!-- PJG 0012 frnewline --> taken to maintain the agency's ability to collect information  <!-- PJG 0012 frnewline --> about safety risks of FDA-regulated products that is vital to  <!-- PJG 0012 frnewline --> protection of the public health.  <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline --> </SUMMARY> <DATE> <!-- PJG ITAG l=10 g=1 f=2 --> DATES: <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 -->  Comments by March 28, 1994. <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline --> </DATE> <ADDRESS> <!-- PJG ITAG l=10 g=1 f=2 --> ADDRESSES: <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 -->  Submit written comments to the Dockets Management  <!-- PJG 0012 frnewline --> Branch (HFA&hyph;305), Food and Drug Administration, rm. 1&hyph;23, 12420  <!-- PJG 0012 frnewline --> Parklawn Dr., Rockville, MD 20857. <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> </ADDRESS> <FURTHER> <!-- PJG ITAG l=10 g=1 f=2 --> FOR FURTHER INFORMATION CONTACT: <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 -->   <!-- PJG 0012 frnewline --> Ilisa B. G. Bernstein,  <!-- PJG 0012 frnewline --> Office of Policy (HF&hyph;23),  <!-- PJG 0012 frnewline --> Food and Drug Administration,  <!-- PJG 0012 frnewline --> 5600 Fishers Lane,  <!-- PJG 0012 frnewline --> Rockville, MD 20857,  <!-- PJG 0012 frnewline --> 301&hyph;443&hyph;2831.  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </FURTHER> <SUPPLEM> <!-- PJG ITAG l=84 g=1 f=2 --> SUPPLEMENTARY INFORMATION: <!-- PJG /ITAG -->  <!-- PJG ITAG l=84 g=1 f=1 -->   <!-- PJG 0012 frnewline --> I. Background  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=83 g=1 f=1 --> A. Introduction  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> A critical public health activity of FDA is to monitor the  <!-- PJG 0012 frnewline --> safety of human drugs, biologics, and devices in the marketplace.  <!-- PJG 0012 frnewline --> As part of postmarketing surveillance programs to monitor the  <!-- PJG 0012 frnewline --> safety of these products, FDA relies heavily on its adverse event  <!-- PJG 0012 frnewline --> reporting systems. These reporting systems are important  <!-- PJG 0012 frnewline --> adjuncts to the product approval process, which is based  <!-- PJG 0012 frnewline --> primarily on testing conducted before a product is marketed.  <!-- PJG 0012 frnewline --> Although preapproval testing provides significant information  <!-- PJG 0012 frnewline --> about the safety and efficacy of a product, not all potential  <!-- PJG 0012 frnewline --> safety problems can be identified in the preapproval stage when  <!-- PJG 0012 frnewline --> the number of subjects exposed to the product and the period of  <!-- PJG 0012 frnewline --> exposure are necessarily limited. For that reason, the receipt  <!-- PJG 0012 frnewline --> of postmarket reports of adverse events associated with a  <!-- PJG 0012 frnewline --> regulated product is critical to the agency's ability to help  <!-- PJG 0012 frnewline --> protect the public health.  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </SUPPLEM> <!-- PJG /STAG --></p>
		</main>
</body></html>
            